Eli Lilly

2. Eli Lilly

Total Ad Spend: $433.4 million
Television: $367.3 million
Magazine: $43.4 million
Other: $22.7 million

Eli Lilly ($LLY) is getting what it can from erectile dysfunction (ED) drug Cialis and antidepressant Cymbalta while the gettin' is good. It loses patent protection late this year on Cymbalta, which has been generating about $5 billion annually. Lilly also keeps pushing Cialis. A recent study criticized the industry for failing to adhere to voluntary guidelines on when such ads will run, pointing out that ads for Cialis and other ED drugs have crept into family viewing time slots. 

In the spotlight

Cymbalta for pain, $165.8 million
Cialis, $162.8 million
Cymbalta for depression, $77.2 million


 

Eli Lilly
Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.